Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Peposertib · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: Peposertib: Treatment Sequence A-B-C | EXPERIMENTAL | Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2, followed by oral suspension dose of peposertib (Treatment C) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period. |
| Part 1: Peposertib Treatment Sequence A-C-B | EXPERIMENTAL | Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by oral suspension dose of peposertib (Treatment C) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment B) on Day 15 under fed condition in period 3. There will be washout period of 7 days between each treatment period. |
| Part 1: Peposertib Treatment Sequence B-A-C | EXPERIMENTAL | Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2, followed by oral suspension dose of peposertib (Treatment C) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period. |
| Part 1: Peposertib Treatment Sequence B-C-A | EXPERIMENTAL | Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by oral suspension dose of peposertib (Treatment C) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment A) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period. |
| Part 1: Peposertib: Treatment Sequence C-A-B | EXPERIMENTAL | Participants will receive oral suspension dose of peposertib (Treatment C) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment B) on Day 15 under fed condition in period 3. There will be washout period of 7 days between each treatment period. |
| Part 1: Peposertib Treatment Sequence C-B-A | EXPERIMENTAL | Participants will receive oral suspension dose of peposertib (Treatment C) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2, followed by single oral dose of peposertib tablet (Treatment A) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period. |
| Part 2: Peposertib Treatment Sequence A-B | EXPERIMENTAL | Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2. There will be washout period of 7 days between each treatment period. |
| Part 2: Peposertib: Treatment Sequence B-A | EXPERIMENTAL | Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2. There will be washout period of 7 days between each treatment period. |
| Name | Type | Description |
|---|---|---|
| Peposertib | DRUG | Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions. |
Inclusion Criteria: * Participants are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring * Participants are nonsmoker for at least 6 months prior to Screening * Participants have a body weight greater than ...
Peposertib is an investigational small molecule being developed by Merck & Company, Inc. (MRK). It is currently in Phase 1 clinical development. As of the available data, it has been studied in healthy volunteers, with one completed trial involving 12 participants.
Peposertib has been studied in healthy volunteers, as part of a Phase 1 clinical trial. The trial was designed to assess the effect of food on the pharmacokinetics of Peposertib. It is not approved for any medical condition and remains in clinical development.
Peposertib is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's properties in healthy subjects.
Peposertib is in Phase 1 clinical development. The only known trial, NCT04702698, has been completed. This trial enrolled 12 healthy participants and was conducted in Germany. Peposertib is not FDA approved and remains an investigational drug.
Peposertib has one completed clinical trial, NCT04702698, titled "Effect of Food on Peposertib PK." This Phase 1 study enrolled 12 healthy volunteers in Germany and evaluated how food affects the drug's pharmacokinetics. The trial was controlled but not double-blinded.
No alternative names for Peposertib have been reported. It is identified solely by its generic name, Peposertib, in clinical trial records. The drug is being developed by Merck & Company, Inc. under this name.